Stockreport

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

Cogent Biosciences, Inc.  (COGT) 
Last cogent biosciences, inc. earnings: 11/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.cogint.com/investor-relations
PDF -   Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. [Read more]